ANAB
AnaptysBio, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +1 | 17.00K | $854,169 | +1 | n/a |
| Q2 2026 | 86 | +7 | 13.42M | $905.56M | +13 | −6 |
| Q1 2026 | 82 | +8 | 12.40M | $687.67M | +10 | −2 |
| Q4 2025 | 74 | -1 | 13.98M | $677.76M | n/a | −1 |
| Q3 2025 | 20 | +1 | 11.93M | $365.35M | +1 | n/a |
| Q2 2025 | 16 | 0 | 9.08M | $201.48M | +1 | −1 |
| Q1 2025 | 13 | +2 | 6.02M | $111.87M | +2 | n/a |
| Q4 2024 | 11 | -2 | 3.90M | $51.60M | n/a | −2 |
| Q3 2024 | 12 | +2 | 2.80M | $93.85M | +2 | n/a |
| Q2 2024 | 10 | n/a | 1.82M | $45.55M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Robeco Institutional Asset… | 16.95K | New | $852,058 | 0.0% | New | 1 | SEC ↗ |
| 2 | Assetmark, Inc | 42 | +16.7% | $2,111 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Robeco Institutional Asset… | $852,058 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 205 holders, 28.23M shares, $1.54B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 5.00K sh · $249,372
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology